Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

2013’s Most Notable Stories In “The Pink Sheet” DAILY

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA budget challenges, biosimilars, R&D revamps and social media are among stories from the past year that captured the attention of readers and reflect major biopharma trends.

You may also be interested in...



European Notebook: AstraZeneca Snuggles Up To Potential Partners In New Cambridge HQ, Viagra Patents Expire In Europe

AstraZeneca's new HQ is to cornerstone a growing U.K. cluster of clinical and research assets; the EU and U.S. start talks on what could be the world's largest free trade agreement; Viagra patent expiry provides a lift for European generic companies; European wholesalers support the liquidity of European health care markets; new pricing system for generics in Ireland.

AstraZeneca’s R&D Restructuring Follows Hot Spot Trend

In its most ambitious overhaul since the reorganization into iMeds in 2010, AstraZeneca’s latest R&D restructuring takes on three basic challenges: accessing innovation, improving internal productivity and reducing complexity and cost. It is the opening salvo in the new CEO’s vision for the troubled pharma.

FDA’s Generics Office Loses Another Director As Geba Makes Quick Exit

Gregory Geba will step down March 15, saying ongoing organizational changes created challenges to implementing his vision; CDER Director Janet Woodcock will run the office during the nationwide search for a replacement.

Topics

Related Companies

UsernamePublicRestriction

Register

PS075215

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel